SIRT4 and breast carcinoma: Importantly, SIRT4 inhibits the phosphorylation and nuclear translocation of STAT3, thereby inhibiting the STAT3 signaling pathway, and amplification of the target genes MYC and CCND1 of the STAT3 signaling pathway provide tamoxifen resistance in ER-positive breast-cancer cells (89, 90).